Passage BIO, Inc. Annual Report - A Performance Summary

Considering an investment in Passage BIO, Inc.? This summary breaks down their past year's performance in clear, accessible language, helping you understand the company's operations and potential fit for your portfolio. We aim to provide a straightforward overview, not a dense financial report.

This summary covers Passage BIO, Inc.'s performance for the fiscal year ended December 31, 2025, drawing structural details from their 10-K filing.

1. Business Overview (What the Company Does)

Passage BIO, Inc. (ticker: PASG) is a genetic medicines company. It focuses on developing treatments for rare diseases, primarily using gene therapy approaches. The company discovers, develops, and commercializes gene therapies delivered via AAV vectors for rare genetic brain and spinal cord disorders. Its pipeline typically includes product candidates at various development stages, from preclinical research through clinical trials (e.g., Phase 1/2, Phase 3), targeting specific genetic diseases. Passage BIO leverages its scientific expertise and proprietary technologies to address unmet medical needs in these rare disease populations.

2. Financial Performance (Revenue, Profit, Year-over-Year Changes)

As a clinical-stage biotechnology company, Passage BIO's financial activities typically involve significant Research and Development (R&D) Expenses and General and Administrative (G&A) Expenses. The filing indicates movements in its Common Stock, Retained Earnings, and Additional Paid-In Capital during 2025, reflecting typical changes in shareholder equity.

For Funding Activities, the company utilized an "At-the-Market" (ATM) Facility Agreement from 2021 through 2025. This program allowed Passage BIO to raise capital to support its operations and pipeline development.

3. Management Discussion (MD&A Highlights)

For the fiscal year 2025, the summary indicates:

• Strategic Collaborations: Passage BIO maintained an "Arrangement with Gemma Biotherapeutics Inc." and an "Amended and Restated Research Collaboration and License Agreement with Penn" (likely the University of Pennsylvania).
• Operational Restructuring and Cost Management: Passage BIO incurred Employee Severance expenses in both 2024 and 2025 and reported the Disposal of Laboratory Equipment in 2025.
• Real Estate Management: The company had several sublease agreements (Sublease Agreement A, B, C, and Market Street Sublease Agreement) in effect or initiated during 2023-2024.

4. Financial Health (Debt, Cash, Liquidity)

Passage BIO manages its liquid assets through various investments, including:

• Money Market Funds
• Demand Deposits
• Commercial Paper
• US Government Debt Securities
• Corporate Debt Securities
• Certificates of Deposit

Passage BIO also has operating lease obligations for both laboratory and office space, which create ongoing financial commitments that impact its liquidity and cash flow.

5. Future Outlook (Guidance, Strategy)

The filing indicates a subsequent event in January 2026 related to "Laboratory Equipment and Certain Other Assets."

The company's long-term strategy supports its equity incentive plans (2020 Equity Incentive Plan, 2021 Equity Inducement Plan, Employee Stock Purchase Plan).